<p><span style="font-weight: 400;">Dans cette 70</span><span style="font-weight: 400;">e</span><span style="font-weight: 400;"> baladodiffusion, les Drs Alexandre Mutchmore et Mathieu Labossière discutent de sémaglutide oral pour la prévention des événements cardiovasculaire chez les personnes avec diabète de type 2, en plus de réviser la littérature médicale de mars 2025.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Quiz clinique (1 min 26), présentation principale (2 min 17), critique (21 min 51), retour sur le cas clinique (29 min 26), autres articles (32 min 34), réponse au quiz clinique (38 min 38)</span></p> <p>&nbsp;</p> <h2><b>Référence principale :</b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025. Epub 2025/03/31 21:17. doi: 10.1056/NEJMoa2501006. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40162642/"><span style="font-weight: 400;">40162642</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <h2><b>Articles associés : </b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/39549716/"><span style="font-weight: 400;">39549716</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/27633186/"><span style="font-weight: 400;">27633186</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019 ;381(9):841-851. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/31185157/"><span style="font-weight: 400;">31185157</span></a><span style="font-weight: 400;">. </span></p> <p>&nbsp;</p> <h2><b>Autres articles d’intérêt récent : </b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2025;392(12):1155-67. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/39555827/"><span style="font-weight: 400;">39555827</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre MA, Meneveau N, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405(10480):725-35. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40023651/"><span style="font-weight: 400;">40023651</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Vodstrcil LA, Plummer EL, Fairley CK, Hocking JS, Law MG, Petoumenos K, et al. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2025;392(10):947-57. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40043236/"><span style="font-weight: 400;">40043236</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Veltkamp R, Korompoki E, Harvey KH, Harvey ER, Fiessler C, Malzahn U, et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2025;405(10482):927-36. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40023176/"><span style="font-weight: 400;">40023176</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <h2><b>Guides de pratique : </b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">Advani SD, Thaden JT, Perez R, Stair SL, Lee UJ, Siddiqui NY. State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women. Clin Infect Dis. 2025;80(3):e31-e42. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40095960/"><span style="font-weight: 400;">40095960</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <h2><b>Références du quiz clinique :</b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/35662478/"><span style="font-weight: 400;">35662478</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Prabhu A, Cargill T, Roberts N, Ryan JD. Systematic Review of the Clinical Outcomes of Iron Reduction in Hereditary Hemochromatosis. Hepatology. 2020 Oct;72(4):1469-1482. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/32500577/"><span style="font-weight: 400;">32500577</span></a><span style="font-weight: 400;">.</span></p>